A double-blind, crossover, non-inferiority randomized controlled trial where primary care providers and patients compare human- and AI-generated digital health messages: the AI-CARE study protocol

IntroductionPrimary care is facing multiple crises, including an increase in health misinformation. Digital health messaging by primary care providers has been shown to reach a diverse patient population. With the uptake of Generative Artificial Intelligence (GenAI) usage in healthcare, there is an important opportunity to rapidly create messages that are tailored to different populations and conditions. However, thoroughly assessing AI-generated content is essential, as GenAI raises concerns regarding its accuracy, understandability, actionability, and bias perpetuation. We aim to investigate whether digital health messages created by GenAI are evaluated as noninferior compared to those created by human experts. Methods and analysisThe AI-CARE (AI to Create Accessible and Reliable patient Education materials) study is a double-blind, crossover, non-inferiority randomized controlled trial. Data collection began on May 30, 2025, and is expected to be completed at the end of April 2026. Over 12 months, 192 messages on 48 topics will be written: half by primary care and public health experts and half by a GenAI tool (OpenAIs ChatGPT). Review Panels composed of 24 primary care providers and 24 patients will evaluate these messages using an Evaluation Grid developed to assess the messages quality of information, adaptation to the target audience, relevance and usefulness, and readiness to be shared with patients. Evaluations will be completed via online REDCap surveys and the order in which the 192 messages appear will be randomized and will vary between individuals. Participants and analysts will be blinded to the generation source. The primary outcome will be the Clarity and Understandability score. Ethics and disseminationThe Research Ethics Boards of the Hopital Montfort (24-25-11-038) and the University of Ottawa (S-12-24-11153) formally approved this study in December 2024. Reported data will be grouped and anonymized for dissemination in peer-reviewed scientific journals and conferences. Trial registration numberNCT06997107 ARTICLE SUMMARYO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIThe AI-CARE study allows for within-participant comparison between human- and AI-generated digital health messages, minimizing variability due to individual differences. C_LIO_LIThe Review Panels are diverse and composed of primary care providers and patients currently practicing in or using the healthcare system in five Canadian provinces. C_LIO_LIThe developed Evaluation Grid allows for the assessment of multiple aspects related to digital health messages: quality of information, adaptability to the target audience, relevance and usefulness, and readiness to be shared with patients. C_LIO_LIOne limitation is that messages generated by AI are created using only one LLM (Open AIs ChatGPT). C_LIO_LIDue to the nature and location of recruitment, we may introduce selection bias (participants already engaged in research and interested in digital communication and AI) and the racial diversity of our study population may be limited. C_LI